| Symbol | SKYE |
|---|---|
| Name | SKYE BIOSCIENCE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11250 EL CAMINO REAL,SUITE 100, SAN DIEGO, California, 92130, United States |
| Telephone | +1 858 410-0266 |
| Fax | — |
| — | |
| Website | https://www.skyebioscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001516551 |
| Description | Skye Bioscience a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders through the development of next-generation molecules that modulate G-protein coupled receptors. Skyes strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Additional info from NASDAQ: |
New Form SCHEDULE 13D/A - Skye Bioscience, Inc. <b>Filed:</b> 2026-08-18 <b>AccNo:</b> 0001873545-26-000007 <b>Size:</b> 32 KB
Read moreSkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Read moreNew Form DEFA14A - Skye Bioscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001628280-26-056979 <b>Size:</b> 6 MB
Read moreDirector DHILLON PUNIT 🟢 acquired 1.1M shares of Skye Bioscience, Inc. (SKYE) Transaction Date: Aug 07, 2026 | Filing ID: 054941
Read moreSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Read moreUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Read moreSkye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Read moreNew Form 3 - Skye Bioscience, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001628280-26-028062 <b>Size:</b> 323 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06577090 | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-adm… | Phase2 | Obesity | Active_Not_Recruiting | 2024-08-22 | 2027-02-28 | ClinicalTrials.gov |
| NCT06144918 | Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic… | Phase2 | Primary Open Angle Glaucoma | Completed | 2023-11-09 | 2024-02-22 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nimacimab 300 mg injection | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| semaglutide injection | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| Nimacimab placebo injection | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| Nimacimab injection | Other | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| SBI-100 Ophthalmic Emulsion, Placebo | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |
| SBI-100 Ophthalmic Emulsion, 1.0% | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |
| SBI-100 Ophthalmic Emulsion, 0.5% | Other | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |
| Nimacimab 300 mg injection | BIOLOGICAL | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| Nimacimab placebo injection | BIOLOGICAL | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| Nimacimab injection | BIOLOGICAL | Phase PHASE2 | Obesity | ACTIVE_NOT_RECRUITING | NCT06577090 |
| SBI-100 Ophthalmic Emulsion, Placebo | DRUG | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |
| SBI-100 Ophthalmic Emulsion, 1.0% | DRUG | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |
| SBI-100 Ophthalmic Emulsion, 0.5% | DRUG | Phase PHASE2 | Primary Open Angle Glaucoma | COMPLETED | NCT06144918 |